LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it is nearing completion of the addition of more than 50,000 square feet to its headquarters and research campus in Lebanon, New Hampshire. Over the past seven years, Adimab has added more than 400 royalty bearing therapeutic programs. To accommodate this continual growth, Adimab has increased headcount by approximately 40% over the past three years.
“We have not expanded the footprint of our main research facility since initially occupying it in 2011,” explained Eric Krauland, President and Chief Scientific Officer of Adimab. “We have grown substantially since then, in terms of both employees and capabilities. This expansion will allow us to continue to offer our partners state-of-the-art protein discovery and engineering, including GPCR target campaigns, TCR engineering, and a wide array of multispecific projects.”
“Adimab has been consistently profitable for more than a decade, a rarity in our industry,” said Ryan McGovern, Chief Financial Officer of Adimab. “Our partner-first approach to dealmaking and technology development has resulted in persistent revenue generation, and our discipline on the expense side allows us to substantially expand our facilities without threatening our profitability.”
Technologies
Antibody discovery: Adimab discovers therapeutic antibodies in IgG and single domain (HCAb) formats through our proprietary yeast-based technology. Adimab can utilize its fully human synthetic diversity as well as additional diversities from in vivo sources. Antibodies from Adimab have exquisite specificity and are utilized as monospecific and multispecific therapies as well as CAR-Ts, ADCs, and other proteins.
Engineering: Adimab has developed and refined its engineering capabilities over thousands of lead antibody optimization efforts. The process starts with one or more partner-selected lead antibodies with the goal of optimizing potency, specificity, and/or developability. These leads can come from Adimab’s discovery process or from outside sources, typically to fix undesirable properties of antibodies from in vivo and phage-based technologies. Adimab also applies its engineering expertise to cytokines, TCRs, and other modalities.
Multispecifics and T cell engagers: Adimab has extensive multispecific capabilities that enable a variety of partner selected formats. In addition to common light chain and fragment-based discovery and engineering, Adimab has the ability to generate large panels of multispecifics for lead selection. Adimab also has proprietary solutions for both Fc (HC:HC) and Fab (HC:LC) heterodimerization to allow for the generation of numerous multispecific product designs with excellent developability properties. These are commonly coupled with Adimab’s highly characterized suite of CD3 and CD28 antibodies to generate multispecific T cell engagers.
Complex targets workflows: Certain membrane-obligate proteins (e.g., GPCRs and ion channels) are poorly behaved outside their native membrane environment. For these targets, Adimab has developed proprietary in vitro and in vivo discovery workflows that allow for discovery against membrane-obligate proteins in their native state. The company has employed these workflows numerous times to generate robust panels of specific antibodies to these classically difficult targets.
About Adimab
Adimab is the leading provider of therapeutic antibody discovery and engineering technologies. This includes naïve discovery from synthetic libraries in yeast or B cells (mice, llama, and humans), antibody engineering and optimization, multi-specific antibody engineering, and a portfolio of proprietary CD3 and CD28 antibodies licensed non-exclusively for multispecific applications. Adimab focuses solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with over 115 pharmaceutical and biotechnology companies, generating more than 525 therapeutic programs, over 70 clinical programs, and several approved products. The Adimab technology has been transferred and implemented at Biogen, GSK, Lilly, Merck, Novo Nordisk, Takeda. Funded discovery partners include leading pharmaceutical companies, such as Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Regeneron, Sanofi, Takeda, Vertex and others. Adimab has also partnered with many early-stage venture-backed companies, including Dragonfly, NextPoint, Tizona, TRex Bio and others, as well as mid-size public biopharmaceutical companies such as Alector, Cullinan Oncology, Innovent, iTeos, Mersana Therapeutics, Santa Ana Bio, Scholar Rock, and others.
Adimab’s integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit http://www.adimab.com.
